Javascript must be enabled to continue!
Abstract 1890: Bispecific T cell engagers targeting TrkB
View through CrossRef
Abstract
Tropomyosin kinase B (TrkB) plays an important role in survival, differentiation, and proliferation of neural cells. It belongs to the family of receptor tyrosine kinases and its specific ligands are NT-4/5 and BDNF. The (over)expression of TrkB and (over)activation of the BDNF/TrkB signaling pathway is implicated in various solid malignancies and associated with poor prognosis due to the role of TrkB in suppressing anoikis and promoting epithelial-mesenchymal transition. Here we present the development and characterization of novel T cell engagers targeting TrkB. A panel of 41 sequence unique antibodies were selected from human phage display libraries and B cells of TrkB-ECD immunized chicken. Following recombinant expression, the panel of antibodies was analyzed for off-rate, binding reactivity to plate-immobilized and cell-expressed TrkB, cross-reactivity to other tropomyosin kinase family members, and competition with BDNF. Based on their characteristics, two targeting arms were prioritized for the generation of T cell engagers using a standard bispecific knob-into-hole approach. Apart from a commercial CD3 targeting arm, three proprietary CD3 targeting arms were also analyzed. After successful production of the bispecifics , the molecules were validated to bind to plate-immobilized TrkB and CD3 separately and cell-associated TrkB and CD3 simultaneously. In addition, our TrkB T cell engagers were able to induce varying levels of T cell activation in vitro. Our data suggests that these TrkB/CD3 bispecific molecules could be interesting candidates for further development into immuno-oncology therapeutics.
Citation Format: Jetta Bijlsma, Srinidhi Desikan, Timothy Miller, Allie Thom, Jennifer Bath, Ilse Roodink. Bispecific T cell engagers targeting TrkB [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1890.
American Association for Cancer Research (AACR)
Title: Abstract 1890: Bispecific T cell engagers targeting TrkB
Description:
Abstract
Tropomyosin kinase B (TrkB) plays an important role in survival, differentiation, and proliferation of neural cells.
It belongs to the family of receptor tyrosine kinases and its specific ligands are NT-4/5 and BDNF.
The (over)expression of TrkB and (over)activation of the BDNF/TrkB signaling pathway is implicated in various solid malignancies and associated with poor prognosis due to the role of TrkB in suppressing anoikis and promoting epithelial-mesenchymal transition.
Here we present the development and characterization of novel T cell engagers targeting TrkB.
A panel of 41 sequence unique antibodies were selected from human phage display libraries and B cells of TrkB-ECD immunized chicken.
Following recombinant expression, the panel of antibodies was analyzed for off-rate, binding reactivity to plate-immobilized and cell-expressed TrkB, cross-reactivity to other tropomyosin kinase family members, and competition with BDNF.
Based on their characteristics, two targeting arms were prioritized for the generation of T cell engagers using a standard bispecific knob-into-hole approach.
Apart from a commercial CD3 targeting arm, three proprietary CD3 targeting arms were also analyzed.
After successful production of the bispecifics , the molecules were validated to bind to plate-immobilized TrkB and CD3 separately and cell-associated TrkB and CD3 simultaneously.
In addition, our TrkB T cell engagers were able to induce varying levels of T cell activation in vitro.
Our data suggests that these TrkB/CD3 bispecific molecules could be interesting candidates for further development into immuno-oncology therapeutics.
Citation Format: Jetta Bijlsma, Srinidhi Desikan, Timothy Miller, Allie Thom, Jennifer Bath, Ilse Roodink.
Bispecific T cell engagers targeting TrkB [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1890.
Related Results
Inhibition of DJ-1 degradation by TrkB promotes the progression and maintenance of traits of cancer stem cells in hepatocellular carcinoma
Inhibition of DJ-1 degradation by TrkB promotes the progression and maintenance of traits of cancer stem cells in hepatocellular carcinoma
Abstract
Although TrkB may be associated with the pathogenesis of various cancer by upregulation, how upregulation of TrkB led to tumor progression in hepatocellular carcin...
Engaging T cells for cleanup
Engaging T cells for cleanup
T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malig...
A review of mono- and bispecific genera of Amphibians worldwide
A review of mono- and bispecific genera of Amphibians worldwide
Monospecific and bispecific genera are of particular interest in studies of taxonomic diversity and speciation evolution. Here, the distribution patterns of mono- and bispecific am...
Physiological basis underlying antidepressant-induced activation of TrkB receptors
Physiological basis underlying antidepressant-induced activation of TrkB receptors
SummaryWe show that both pharmacological and non-pharmacological treatments of depression activate TrkB receptors—a well-established target of antidepressants—by inducing a physiol...
Reduced enteric BDNF-TrkB signaling drives stress-dependent glucocorticoid-mediated GI dysmotility
Reduced enteric BDNF-TrkB signaling drives stress-dependent glucocorticoid-mediated GI dysmotility
Abstract
Stress is a key contributor to gastrointestinal (GI) dysmotility, particularly in patients with disorders of gut-brain interactions (DGB...
Abstract 4240: In vivo assessment of AICD and cytokine release upon treatment of OKT3 and CD3 bispecific antibody in homozygous CD3EDG HuGEMM™
Abstract 4240: In vivo assessment of AICD and cytokine release upon treatment of OKT3 and CD3 bispecific antibody in homozygous CD3EDG HuGEMM™
Abstract
Introduction: CD3 bispecific antibodies have transformed the therapeutic landscape of immunotherapy for some hematological malignancies, however, the clinic...
Dysfunction of the BDNF-TrkB signaling pathway contributes to learning and memory impairments induced by neuroinflammation in mice
Dysfunction of the BDNF-TrkB signaling pathway contributes to learning and memory impairments induced by neuroinflammation in mice
Background and Purpose: Evidence suggests neuroinflammation is the main
mechanism in cognitive dysfunction. The brain-derived neurotrophic
factor (BDNF) is involved in learning and...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...

